Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (NASDAQ: FATE), AveXis Inc (NASDAQ: AVXS) and aTyr Pharma (NASDAQ: LIFE)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fate Therapeutics (NASDAQ: FATE), AveXis Inc (NASDAQ: AVXS) and aTyr Pharma (NASDAQ: LIFE).

Fate Therapeutics (NASDAQ: FATE)

BMO Capital analyst Do Kim reiterated a Buy rating on Fate Therapeutics (NASDAQ: FATE) yesterday and set a price target of $7. The company’s shares closed yesterday at $4.64.

According to TipRanks.com, Kim is a 5-star analyst with an average return of 28.9% and a 69.4% success rate. Kim covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Vertex Pharmaceuticals, and Cynapsus Therapeutics.

Fate Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $7.

AveXis Inc (NASDAQ: AVXS)

In a report released yesterday, Ian Somaiya from BMO Capital reiterated a Buy rating on AveXis Inc (NASDAQ: AVXS), with a price target of $95. The company’s shares closed yesterday at $72.78, close to its 52-week high of $75.87.

According to TipRanks.com, Somaiya is a 5-star analyst with an average return of 17.1% and a 64.4% success rate. Somaiya covers the Healthcare sector, focusing on stocks such as Aeglea Biotherapeutics Inc, Corcept Therapeutics Inc, and Protagonist Therapeutics.

AveXis Inc has an analyst consensus of Strong Buy, with a price target consensus of $87.

aTyr Pharma (NASDAQ: LIFE)

BMO Capital analyst Matthew Luchini reiterated a Hold rating on aTyr Pharma (NASDAQ: LIFE) yesterday and set a price target of $4. The company’s shares closed yesterday at $3.80.

According to TipRanks.com, Luchini is a 1-star analyst with an average return of -1.5% and a 46.2% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Alder Biopharmaceuticals, and Spark Therapeutics.

aTyr Pharma has an analyst consensus of Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.